Pharsight

Prezcobix is owned by Janssen Prods.

Prezcobix contains Cobicistat; Darunavir.

Prezcobix has a total of 6 drug patents out of which 0 drug patents have expired.

Prezcobix was authorised for market use on 29 January, 2015.

Prezcobix is available in tablet;oral dosage forms.

Prezcobix can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.

The generics of Prezcobix are possible to be released after 06 October, 2032.

Application	Filing Date	Opposition Party	Legal Status
EP16180589A	2020-10-08	Cooke, Richard	Granted and Under Opposition
EP16180589A	2020-10-06	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP16180589A	2020-01-10	STADA Arzneimittel AG	Granted and Under Opposition
EP14168686A	2018-04-12	Cooke, Richard	Opposition rejected
EP12167591A	2017-05-17	Cooke, Richard	Revoked
EP12167590A	2017-05-17	Cooke, Richard	Revoked
EP12167591A	2017-05-16	Teva Pharmaceutical Industries LTD.	Revoked
EP12167590A	2017-05-16	Teva Pharmaceutical Industries LTD.	Revoked
EP12167589A	2017-05-10	Cooke, Richard	Granted and Under Opposition
EP12167589A	2017-05-09	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP12167596A	2017-04-27	Cooke, Richard	Revoked
EP12167596A	2017-04-25	Teva Pharmaceutical Industries Ltd	Revoked
EP09739981A	2016-06-30	Cooke, Richard	Revoked
EP09739981A	2016-06-29	Teva Pharmaceutical Industries Ltd	Revoked
EP10703766A	2016-04-29	Cooke, Richard	Revoked
EP10703766A	2016-04-22	Teva Pharmaceutical Industries Ltd	Revoked
EP07836007A	2016-03-17	Trösch, Dominique	Granted and Under Opposition
EP07836007A	2016-03-17	Georg Kalhammer/Stephan Teipel	Granted and Under Opposition
EP07836007A	2016-03-16	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP03753571A	2015-03-18	Wittkopp, Alexander	Patent maintained as amended
EP10180831A	2015-03-18	Wittkopp, Alexander	Patent maintained as amended
EP03753571A	2015-03-17	Strawman Limited	Patent maintained as amended
EP10180831A	2015-03-17	Strawman Limited	Patent maintained as amended
EP03753571A	2015-03-06	Alfred E. Tiefenbacher (GmbH & Co. KG)	Patent maintained as amended
EP10180831A	2015-03-06	Alfred E. Tiefenbacher (GmbH & Co. KG)	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8518987	April, 2015	Terminated-Denied	Janssen Sciences Ireland UC	Lupin Limited

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Feb, 2024 (8 months from now)
US7700645	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Dec, 2026 (3 years from now)
US8148374	JANSSEN PRODS	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987 (Pediatric)	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Aug, 2024 (1 year, 2 months from now)
US7700645 (Pediatric)	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Jun, 2027 (4 years from now)
US10039718	JANSSEN PRODS	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; Treatment of hiv infection in adults and pediatric patients weighing a...

Dosage: TABLET;ORAL